Acute treatments: future developments.
In Chapter 14, blind alleys in acute anti-migraine drug development were discussed. In this chapter, future therapies are covered. There is growing interest and support for the use of CGRP antagonists, nitric oxide synthase inhibitors, and ionotropic glutamate receptor antagonists. The hope is to strike the balance of high efficacy with minimal to no safety concern and good tolerability. Some of the targets discussed in this chapter have been in early efficacy trials and others are in first human dose stages. Large-scale efficacy and safety trials are eagerly awaited.
Ramadan
N M
NM
Lilly Research Laboratories, Eli Lilly & Co. and Indiana University School of Medicine, Indianapolis, Indiana 46285, USA. ramadan@lilly.com
D015740:Calcitonin Gene-Related Peptide / Q000037:antagonists & inhibitors; D005544:Forecasting; D006801:Humans; D007608:Kainic Acid / Q000037:antagonists & inhibitors; D008881:Migraine Disorders / Q000188:drug therapy*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid / Q000037:antagonists & inhibitors
D017366:Serotonin Receptor Agonists; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; D019001:Nitric Oxide Synthase; D015740:Calcitonin Gene-Related Peptide; D007608:Kainic Acid